GlassScriptPhysician profile
Srilata Gundala
NPI 1467646141
$10,861.90
in general payments reported to CMS, 2019-2025
69 companies · $3,631 in 2025
The $3,631 reported for 2025 was more than what 77% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $271 · 2021: $643 · 2022: $912 · 2023: $1,984 · 2024: $2,899 · 2025: $3,631.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,820 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,819.84 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $414.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,931.33 | 2021-2025 | |
| Genentech USA, INC. | $870.78 | 2019-2025 | Tecentriq, Perjeta, Phesgo |
| Janssen Biotech, INC. | $663.97 | 2019-2025 | Talvey, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $643.19 | 2019-2025 | Imfinzi, Tagrisso, Enhertu |
| Pfizer INC. | $532.83 | 2019-2025 | |
| Lilly USA, LLC | $501.09 | 2022-2025 | Jaypirca, Verzenio, Retevmo |
| Celgene Corporation | $497.13 | 2020-2025 | Reblozyl, Pomalyst |
| Merck Sharp & Dohme LLC | $362.93 | 2019-2025 | Keytruda, Lynparza |
| Daiichi Sankyo INC. | $320.54 | 2019-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $299.54 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Abbvie INC. | $290.71 | 2023-2025 | |
| Genzyme Corporation | $255.28 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.26 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Incyte Corporation | $226.72 | 2019-2025 | Jakafi |
| Amneal Pharmaceuticals LLC | $201.51 | 2023-2025 | Avastin, Alymsys, Neulasta |
Show all 61 companies
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srilata Gundala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.